Versant spinout lands $80M to go 'much broader' than the old Roche partnership that birthed it

Nicole DeFeudis

Editor

About three years after splitting from Versant Ventures’ discovery group, Pipeline Therapeutics has landed an $80 million Series C round to go “much broader” than …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Versant spinout lands $80M to go 'much broader' than the old Roche partnership that birthed it

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ver­sant spin­out lands $80M to go 'much broad­er' than the old Roche part­ner­ship that birthed it

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Versant spinout lands $80M to go 'much broader' than the old Roche partnership that birthed it